Loading…
← CockpitCompetitor Analysis › ANURAS.NS Anupam Rasayan IndiaOpen in the cockpit ↗

Anupam Rasayan IndiaANURAS.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Custom synthesis and manufacturing (CDMO) of specialty chemicals mainly for global agrochemical and pharmaceutical companies.

≈ A specialty-chemical custom manufacturer for agrochem/pharmaMomentum strong 73
Mkt cap
$1.61B
US dollars, full cap
Free float
27%
of shares outstanding
$/day
$6.67M
20-day average traded
Fwd P/E
49.9×
forward earnings
ROIC−WACC
-11.2 pp
WACC 14.4%
Hurdle
n/a
no reverse DCF
Next earnings
92 days
18 Feb 2027
Close · INR₹1,321
1D+0.3%
1W+10.8%
1M+19.1%
3M+9.1%
6M-3.0%
YTD+0.2%
1Y+23.3%
ATR %2.6%
Beta0.40
52w lowhigh6.6% off high

What Anupam Rasayan India does

Custom synthesis and manufacturing (CDMO) of specialty chemicals mainly for global agrochemical and pharmaceutical companies.

Makes intermediates to a customer's own molecule under long-term contracts, often exclusive, so the buyer supplies the design and Anupam the chemistry and plant capacity. A small number of global agrochemical companies account for much of sales.

In one line: A specialty-chemical custom manufacturer for agrochem/pharma.

Products and services

  • Agrochemical intermediates
  • Pharma intermediates
  • Specialty chemicals

Customers

  • Global agrochemical majors
  • Pharma companies

Where it sits in the supply chain

  • Chemical synthesis R&D
  • Custom manufacturing (CDMO)
  • Sale to global agrochem/pharma majors

What could go right

  • Agrochemical China+1 sourcing shift
  • New long-term supply contracts

What could go wrong

  • Customer concentration
  • Agrochemical demand cyclicality

Moat: narrow (process know-how, customer qualification). Long-term supply contracts tied to a customer's registered molecule create switching costs.

Headquarters: Surat, India · Founded: 1984 · Employees: 2,931

Named competitors

Anupam Rasayan India at a glance

Size Anupam Rasayan India (ANURAS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.61B, the 448th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,321 on 18 Nov 2026.

Performance Over six months the shares fell 3.0%, against -7.7% for the median peer and +3.8% for the India market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue grew 23.8% over the last twelve months (peer median +6.6%); the operating margin is 16.3% (peer median 12.0%).

Valuation It trades at 49.9× forward earnings against a peer median of 23.8× (3rd most expensive of 15).

Capital Return on invested capital runs 11.2 points below its cost of capital (14.4% WACC).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026ANURAS.NS 96Peer median 92
Six months, rebased to 100: Anupam Rasayan India against the median of its 20 peers (local-currency closes).

Anupam Rasayan India financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹26.1B₹23.6B₹14.3B₹14.7B₹15.9B
Revenue growth—+65%-2%-8%—
Gross profit₹9.41B₹5.31B₹4.05B₹4.02B₹4.51B
EBITDA₹6.14B₹5.40B₹4.03B₹3.81B₹4.28B
Net income₹1.80B₹1.70B₹933M₹1.29B₹1.81B
Free cash flown/a-₹3.57B-₹5.45B-₹7.39B₹141M
Capital expendituren/a₹5.55B₹4.10B₹7.16B₹2.21B
Total debt₹25.3B₹18.7B₹14.3B₹10.7B₹8.22B

Quarterly statements and history in the cockpit →

Anupam Rasayan India competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%301047002755ASTRAZEN600420000766JUBLPHARMA0026750020191681SRPT300357INDGN600572600993CAPLIPOINT300723603235FAEMAZEANURAS.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Anupam Rasayan India is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×60×301047002755600420JUBLPHARMA0026750020191681300357INDGN600572600993CAPLIPOINT300723FAEANURAS.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Anupam Rasayan India is the large dot.

Anupam Rasayan India competitors and peer comparison

Head to head with its named competitors (ANURAS.NS vs PIIND.NS vs SRF.NS vs NAVINFLUOR.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Anupam Rasayan India ANURAS.NS$1.61B-3%+24%16%49.9×n/a
PI Industries PIIND.NS$2.63B-48%-15%13%31.6×n/a
Srf SRF.NS$7.77B-7%+20%19%30.0×25.5%
Navin Fluorine International NAVINFLUOR.NS$5.66B+45%+46%30%51.6×37.0%

How Anupam Rasayan India compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Anupam Rasayan India against its 20 peers (data as of 18 Nov 2026)
MeasureANURAS.NSPeer medianRank in peer set
1-month return+19.1%-3.9%highest of 21
6-month return-3.0%-7.7%9th highest of 20
Distance from 52-week high-6.6%-33.2%2nd highest of 21
Revenue growth (TTM)+23.8%+6.6%4th highest of 20
Operating margin16.3%12.0%7th highest of 20
Forward P/E49.9×23.8×3rd most expensive of 15
ROIC minus cost of capital-11.2 pp+1.2 pp4th lowest of 21
EV / EBITDA30.7×17.1×2nd most expensive of 7
Net debt / EBITDA2.8×-1.1×2nd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%49.9×n/an/a
Sino Biological 301047.SZChina$1.60B+27%+20%17%51.6×31.1%-15.1%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%57.4×12.8%-14.0%
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%n/a42.4%+23.0%
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%12.6×-6.6%-5.6%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%29.0×n/an/a
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%47.2×6.0%-4.3%
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%25.6×n/an/a
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%n/a-6.8%+32.4%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%16.0×-6.1%+1.9%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%n/a-4.9%+0.2%
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a

Questions

Who are Anupam Rasayan India's main competitors?
Named competitors: PI Industries (PIIND.NS), SRF Limited (SRF.NS), Navin Fluorine (NAVINFLUOR.NS). The cockpit's measured peer set (industry) also includes Sino Biological (301047.SZ), Beijing Aosaikang Pharmaceutical (002755.SZ), AstraZeneca Pharma India (ASTRAZEN.NS), Shanghai Shyndec Pharmaceutical (600420.SS), Tonghua Golden-Horse Pharmaceutical Industry (000766.SZ), Jubilant Pharmova (JUBLPHARMA.NS).
Is Anupam Rasayan India expensive compared with its peers?
On forward p/e it trades at 49.9× against a peer median of 23.8×, 3rd most expensive of 15 in its peer set.
How has Anupam Rasayan India stock performed?
Over six months to 18 Nov 2026 the shares returned -3.0% against -7.7% for the median peer; over one year +23.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.